Toovey S, Hudson E, Hendry W F, Levi A J
Gut. 1981 Jun;22(6):445-51. doi: 10.1136/gut.22.6.445.
Earlier observations on infertility related to sulphasalazine treatment were extended and semen samples obtained from 28 patients with inflammatory bowel disease on treatment with sulphasalazine at 2-4 g per day. Semen was examined for changes in density, motility, and morphology before, during, and after withdrawal of sulphasalazine. Gross semen abnormalities were seen in 18 patients on this drug for more than two months. Semen quality improved after sulphasalazine had been withdrawn for more than two months and 10 pregnancies are reported after sulphasalazine withdrawal. Preliminary endocrine and acetylator phenotype studies do not elucidate the mechanism of this important new side-effect of this drug. The time course of the drug's effect on semen quality is consistent with the hypothesis that sulphasalazine or a metabolite, possibly sulphapyridine, is directly toxic to developing spermatozoa. These studies confirmed the preliminary report and suggest that prolonged treatment with sulphasalazine may universally depress semen quality and cause reversible infertility.
早期关于柳氮磺胺吡啶治疗导致不育的观察结果得到了扩展，从28例每天服用2 - 4克柳氮磺胺吡啶进行炎症性肠病治疗的患者中获取了精液样本。在服用柳氮磺胺吡啶之前、期间和停药后，对精液进行密度、活力和形态变化的检查。18例服用此药超过两个月的患者出现了明显的精液异常。在停用柳氮磺胺吡啶两个多月后，精液质量有所改善，且据报道在停药后有10例妊娠。初步的内分泌和乙酰化酶表型研究未能阐明该药物这一重要新副作用的机制。药物对精液质量影响的时间进程与柳氮磺胺吡啶或其代谢产物（可能是磺胺吡啶）对发育中的精子直接有毒性这一假设相符。这些研究证实了初步报告，并表明长期使用柳氮磺胺吡啶可能普遍降低精液质量并导致可逆性不育。
